Comparison of intravitreal preservative-free triamcinolone versus posterior sub-tenon triamcinolone acetonide injection for bevacizumab-resistant diabetic macular edema

Table 1 Baseline demographics and characteristics of 40 eyes in 40 patients with bevacizumab-resistant refractory DME

Patient characteristics	IVTA	STTA	P value
Number of eyes	20	20
Mean age (years)	66.53 ± 8.19	64 ± 8.63	0.158
Sex (n, %)			0.102
Male	9 (45%)	8 (40%)
Female	11 (55%)	12 (60%)
DM duration (years)	16.95 ± 7.69	15.5 ± 9.29	0.629
HbA1c (%)	7.41 ± 1.67	7.56 ± 1.68	0.763
Number of previous intravitreal bevacizumab injection (n)	4.05 ± 2.01	4.25 ± 2.9	0.529
Type of DME (n, %)			0.151
Diffuse type	18 (90%)	17 (85%)
Focal type	2 (10%)	3 (15%)
Status of diabetic retinopathy (n, %)			0.568
Moderate NPDR	2 (10%)	3 (15%)
Severe NPDR	4 (20%)	1 (5%)
PDR	14 (70%)	16 (80%)
Previous conventional laser (n, %)			0.151
PRP	18 (90%)	17 (85%)
None	2 (10%)	3 (15%)
Status of lens (n, %)			0.100
Phakic	9 (45%)	10 (50%)
Pseudophakic	11 (55%)	10 (50%)
Mean baseline BCVA (logMAR)	0.75 ± 0.55	0.6 ± 0.36	0.522
Mean baseline CMT (µm)	400.2 ± 144.42	446.65 ± 120.74	0.402
Mean baseline IOP (mmHg)	17.2 ± 2.75	17.65 ± 2.37	0.662

BCVA, best-corrected visual acuity; CMT, central macular thickness; DM, diabetes mellitus; DME, diabetic macular edema; IOP, intraocular pressure; IVTA, intravitreal triamcinolone acetonide injection; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation; SRD, serous retinal detachment; STTA, sub-Tenon’s capsule triamcinolone acetonide injection
* p < 0.05

ISSN: 1471-2415